Multiple site place-of-care manufactured anti-CD19 CAR-T cells induce high remission rates in B-cell malignancy patients

Chimeric antigen receptor (CAR) T cells targeting the CD19 antigen are effective in treating adults and children with B-cell malignancies. Place-of-care manufacturing may improve performance and accessibility by obviating the need to cryopreserve and transport cells to centralized facilities. Here w...

Descripción completa

Detalles Bibliográficos
Autores principales: Maschan, Michael, Caimi, Paolo F., Reese-Koc, Jane, Sanchez, Gabriela Pacheco, Sharma, Ashish A., Molostova, Olga, Shelikhova, Larisa, Pershin, Dmitriy, Stepanov, Alexey, Muzalevskii, Yakov, Suzart, Vinicius G., Otegbeye, Folashade, Wald, David, Xiong, Ying, Wu, Darong, Knight, Adam, Oparaocha, Ibe, Ferencz, Beatrix, Roy, Andre, Worden, Andrew, Kruger, Winfried, Kadan, Michael, Schneider, Dina, Orentas, Rimas, Sekaly, Rafick-Pierre, de Lima, Marcos, Dropulić, Boro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8664838/
https://www.ncbi.nlm.nih.gov/pubmed/34893603
http://dx.doi.org/10.1038/s41467-021-27312-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8664838/
https://www.ncbi.nlm.nih.gov/pubmed/34893603
http://dx.doi.org/10.1038/s41467-021-27312-6

Ejemplares similares